28099754|t|Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward
28099754|a|Considerable data and media attention have highlighted a potential " crisis " in the treatment of osteoporosis. Specifically, despite the availability of several effective drugs to prevent fractures, many patients who need pharmacological therapy are either not being prescribed these medications or if prescribed a medication, are simply not taking it. Although there are many reasons for this "gap" in the treatment of osteoporosis, a major factor is physician and patient concerns over the risk of side effects, especially atypical femur fractures (AFFs) related to bisphosphonate (and perhaps other antiresorptive) drug therapy. In this perspective, we review the current state of undertreatment of patients at increased fracture risk and suggest possible short-, intermediate-, and long-term approaches to address patient concerns, specifically those related to AFF risk. We suggest improved patient and physician education on prodromal symptoms, extended femur scans using dual-energy X-ray absorptiometry (DXA) to monitor patients on antiresorptive treatment, better identification of high - risk patients perhaps using geometrical parameters from DXA and other risk factors, and more research on pharmacogenomics to identify risk markers. Although not the only impediment to appropriate treatment of osteoporosis, concern over AFFs remains a major issue and one that needs to be resolved for effective dissemination of existing treatments to reduce fracture risk. Â© 2017 American Society for Bone and Mineral Research.
28099754	15	21	Crisis	T033	C0231224
28099754	29	38	Treatment	T061	C0087111
28099754	42	54	Osteoporosis	T047	C0029456
28099754	84	88	data	T078	C1511726
28099754	93	98	media	T170	C0009458
28099754	99	108	attention	T041	C0004268
28099754	128	137	potential	T080	C3245505
28099754	140	146	crisis	T033	C0231224
28099754	156	165	treatment	T061	C0087111
28099754	169	181	osteoporosis	T047	C0029456
28099754	209	224	availability of	T169	C0470187
28099754	233	242	effective	T080	C1704419
28099754	243	248	drugs	T121	C0013227
28099754	260	269	fractures	T037	C0016658
28099754	276	284	patients	T101	C0030705
28099754	294	317	pharmacological therapy	T061	C0013216
28099754	339	349	prescribed	T058	C0278329
28099754	356	367	medications	T121	C0013227
28099754	374	384	prescribed	T058	C0278329
28099754	387	397	medication	T121	C0013227
28099754	479	488	treatment	T061	C0087111
28099754	492	504	osteoporosis	T047	C0029456
28099754	514	520	factor	T169	C1521761
28099754	524	533	physician	T097	C0031831
28099754	538	545	patient	T101	C0030705
28099754	546	554	concerns	T078	C2699424
28099754	564	568	risk	T078	C0035647
28099754	572	584	side effects	T046	C0879626
28099754	597	621	atypical femur fractures	T037	C3160754
28099754	623	627	AFFs	T037	C3160754
28099754	640	654	bisphosphonate	T121	C2267018
28099754	674	688	antiresorptive	T121	C0521941
28099754	690	702	drug therapy	T061	C0013216
28099754	756	770	undertreatment	T033	C0237227
28099754	774	782	patients	T101	C0030705
28099754	786	795	increased	T081	C0205217
28099754	796	804	fracture	T037	C0016658
28099754	805	809	risk	T078	C0035647
28099754	831	837	short-	T081	C1806781
28099754	839	852	intermediate-	T082	C0205103
28099754	858	867	long-term	T079	C0443252
28099754	868	878	approaches	T082	C0449445
28099754	890	897	patient	T101	C0030705
28099754	898	906	concerns	T078	C2699424
28099754	938	941	AFF	T037	C3160754
28099754	942	946	risk	T078	C0035647
28099754	959	967	improved	T033	C0184511
28099754	968	975	patient	T101	C0030705
28099754	980	989	physician	T097	C0031831
28099754	990	999	education	T185	C0013622
28099754	1003	1021	prodromal symptoms	T184	C3494358
28099754	1032	1037	femur	T023	C0015811
28099754	1038	1043	scans	T060	C0441633
28099754	1050	1082	dual-energy X-ray absorptiometry	T060	C1510486
28099754	1084	1087	DXA	T060	C1510486
28099754	1092	1108	monitor patients	T058	C0030695
28099754	1112	1126	antiresorptive	T121	C0521941
28099754	1127	1136	treatment	T061	C0087111
28099754	1138	1144	better	T080	C0332272
28099754	1145	1159	identification	T080	C0205396
28099754	1163	1167	high	T080	C0205250
28099754	1170	1174	risk	T078	C0035647
28099754	1175	1183	patients	T101	C0030705
28099754	1198	1220	geometrical parameters	T077	C0549193
28099754	1226	1229	DXA	T060	C1510486
28099754	1240	1252	risk factors	T033	C0035648
28099754	1275	1291	pharmacogenomics	T091	C1138555
28099754	1304	1316	risk markers	T080	C1519104
28099754	1366	1375	treatment	T061	C0087111
28099754	1379	1391	osteoporosis	T047	C0029456
28099754	1393	1400	concern	T078	C2699424
28099754	1406	1410	AFFs	T037	C3160754
28099754	1427	1432	issue	T033	C0033213
28099754	1458	1466	resolved	T033	C3714811
28099754	1471	1480	effective	T080	C1704419
28099754	1481	1494	dissemination	T082	C0205221
28099754	1507	1517	treatments	T061	C0087111
28099754	1528	1536	fracture	T037	C0016658
28099754	1537	1541	risk	T078	C0035647